William Blair analyst Myles Minter has reiterated their bullish stance on NTLA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ strategic advancements and promising clinical developments. The company has expanded the enrollment for its Phase III MAGNITUDE study of Nex-z in ATTR-CM, increasing the total number of participants to 1,200 from the initially expected 765. This decision is driven by higher-than-anticipated enrollment dynamics and aims to enhance the trial’s power to demonstrate cardiovascular outcomes benefits alongside existing TTR stabilizer therapies.
Minter also notes the company’s progress with lonvo-z for HAE, where recruitment for the Phase III HAELO study was completed efficiently, with a significant portion of participants enrolled in a short time frame. The company is on schedule to submit a Biologics License Application (BLA) for lonvo-z in the latter half of 2026. These developments, coupled with the company’s stable financial outlook, which anticipates a cash runway extending into the first half of 2027, underpin Minter’s optimistic Buy rating for Intellia Therapeutics.
According to TipRanks, Minter is a 4-star analyst with an average return of 11.4% and a 52.00% success rate. Minter covers the Healthcare sector, focusing on stocks such as Moderna, Arcturus Therapeutics, and Axsome Therapeutics.
In another report released today, RBC Capital also maintained a Buy rating on the stock with a $21.00 price target.